APVO Profile
Aptevo Therapeutics Inc., headquartered in Seattle, Washington, is a clinical-stage biotechnology company dedicated to developing immunotherapeutic candidates for treating various forms of cancer in the United States. The company's lead clinical candidate, APVO436, is a bispecific T-cell engaging antibody currently undergoing a Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. This innovative treatment aims to harness the body's immune system to target and destroy cancer cells, representing a significant advancement in cancer therapy.
In addition to APVO436, Aptevo Therapeutics has a robust pipeline of preclinical candidates, including ALG.APV-527. This investigational bispecific ADAPTIR candidate targets 4-1BB (CD137) and 5T4, a tumor antigen found in various cancers, potentially enhancing the immune response against tumors. Another promising candidate, APVO603, is a dual agonist bispecific antibody designed to target 4-1BB and OX40, which are crucial for activating and sustaining the immune response against cancer cells.
The company's innovative approach extends to APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology. APVO442 is designed to enhance the biodistribution of drugs to PSMA-positive tumors, offering a targeted treatment for prostate cancer. This platform technology aims to improve the efficacy and safety of cancer therapies by delivering drugs more precisely to tumor sites, minimizing side effects and maximizing therapeutic outcomes.
Aptevo Therapeutics has also entered into a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. This partnership leverages the expertise of both companies to advance the development of novel immunotherapeutic treatments. Founded in 2016, Aptevo Therapeutics continues to focus on innovative approaches to cancer treatment, striving to bring new, effective therapies to patients in need. Through its commitment to scientific excellence and strategic collaborations, the company aims to make a significant impact on the field of oncology.
|
